In a more recent report, Knutson et al (2002) showed that immunisation of four patients with breast or ovarian cancer with HER-2(9369) plus GM-CSF resulted in increased peptide-specific T-cell precursor frequencies (PF) in two of them. Here, ERBB2 is linked to ovarian cancer.